SGLT2i = sodium-glucose cotransporter-2 inhibitor; GLP-1RA = glucagon-like peptide-1 receptor agonist; MACE = major adverse cardiovascular events; MI = myocardial infarction; CV = cardiovascular; HHF = hospitalization for heart failure; eGFR = estimated glomerular filtration rate; RRT = renal replacement therapy; ESKD = end-stage kidney disease; Pbo = placebo. Here, SLC5A2 is linked to heart failure.